Table 1. Completed phase III clinical trials of targeted therapy in advanced hepatocellular cancer.
| Author, year | Treatment (setting) | Molecular targets | Number | Median TTP (months) | Median OS (months) |
|---|---|---|---|---|---|
| Llovet, 2008 (6) | Sorafenib vs. placebo (1st line) | VEGFR, PDGR, RAF, c-kit | 602 | 5.5 vs. 2.8 | 10.9 vs. 6.5 |
| Cheng, 2009 (60) | Sorafenib vs. placebo (1st line) | VEGFR, PDGR, RAF, c-kit | 271 | 2.8 vs. 1.4 | 6.5 vs. 4.2 |
| Cheng, 2013 (68) | Sorafenib vs. sunitinib (1st line) | VEGFR, PDGR, RAF, c-kit, RET | 1,074 | 4 vs. 3.8 | 10.2 vs. 7.8 |
| Johnson, 2013 (67) | Sorafenib vs. brivanib (1st line) | VEGFR, FGFR | 1,155 | 4.2 vs. 4.1 | 9.8 vs. 9.9 |
| Cainap, 2015 (69) | Sorafenib vs. linifanib (1st line) | VEGFR, PDGFR | 1,035 | 4 vs. 5.4 | 9.8 vs. 9.1 |
| Zhu, 2015 (71) | Sorafenib vs. sorafenib and erlotinib (1st line) | EGFR | 720 | 4 vs. 3.2 | 8.5 vs. 9.5 |
| Bruix, 2016 (73) | Regorafenib vs. placebo (2nd line) | VEGFR, PDGFR, Tie-2, B-Raf, RET, c-kit | 573 | 3.2 vs. 1.5 | 10.6 vs. 7.8 |
| Llovet, 2013 (74) | Brivanib vs. placebo (2nd line) | VEGFR, FGFR | 395 | 4.2 vs. 2.7 | 9.4 vs. 8.2 |
| Zhu, 2014 (75) | Everolimus vs. placebo (2nd line) | mTOR pathway | 546 | 3 vs. 2.6 | 7.6 vs. 7.3 |
| Zhu, 2015 (76) | Ramucirumab vs. placebo (2nd line) | VEGFR2 | 565 | 3.5 vs. 2.5 | 9.2 vs. 7.6 |
VEGFR, vascular endothelial growth factor receptor; PDGR, platelet derived growth factor receptor; RAF, rapidly accelerated fibrosarcoma; RET, rearranged during transfection,; FGFR, fibroblast growth factor receptor; EGFR, epidermal growth factor receptor; mTOR, mammalian target of rapamycin.